We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
Read MoreHide Full Article
Clinical-stage biopharmaceutical company, CureVac N.V. (CVAC - Free Report) , announced that its phase IIb/III study on COVID-19 vaccine candidate, CVnCoV, will continue following the first interim analysis in 59 eligible COVID-19 cases.
The independent Data Safety Monitoring Board (DSMB) confirmed that the phase IIb/III study (HERALD) for CVnCoV has passed the first interim analysis in 59 adjudicated COVID-19 cases with no safety concerns.
Consequently, the trial will continue to collect sufficient data in order to conduct a statistically significant efficacy analysis.
We note that the HERALD study has enrolled approximately 40,000 participants in ten countries in Latin America and Europe. The primary objective of the study is to demonstrate the efficacy of a two-dose administration of 12µg of CVnCoV in preventing COVID-19 infection of any severity in participants without prior exposure to SARS-CoV-2.
It is being conducted in an environment characterized by the spread of multiple virus strains. COVID-19 cases within the trial are currently being sequenced to provide critical complementary data to the efficacy readout.
CureVac has no access to the trial data.
We note that the company began the development of mRNA-based COVID-19 vaccine candidates in January 2020. CVnCoV is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs).
In December 2020, CureVac initiated the HERALD study with a 12µg dose of CVnCoV. In February 2021, it initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV.
Last month, CureVac along with partner GlaxoSmithKline (GSK - Free Report) announced the first preclinical data in a rat model, which showed that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
CureVac’s stock has surged 37.4% in the year so far against the industry’s decline of 4.1%.
Image Source: Zacks Investment Research
There is a significant need for different vaccines across the globe to respond effectively to the emerging variants of COVID-19. Currently, players like Pfizer (PFE - Free Report) / BioNTech and Moderna (MRNA - Free Report) are leading the vaccine race with their approved vaccines.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
Image: Bigstock
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
Clinical-stage biopharmaceutical company, CureVac N.V. (CVAC - Free Report) , announced that its phase IIb/III study on COVID-19 vaccine candidate, CVnCoV, will continue following the first interim analysis in 59 eligible COVID-19 cases.
The independent Data Safety Monitoring Board (DSMB) confirmed that the phase IIb/III study (HERALD) for CVnCoV has passed the first interim analysis in 59 adjudicated COVID-19 cases with no safety concerns.
Consequently, the trial will continue to collect sufficient data in order to conduct a statistically significant efficacy analysis.
We note that the HERALD study has enrolled approximately 40,000 participants in ten countries in Latin America and Europe. The primary objective of the study is to demonstrate the efficacy of a two-dose administration of 12µg of CVnCoV in preventing COVID-19 infection of any severity in participants without prior exposure to SARS-CoV-2.
It is being conducted in an environment characterized by the spread of multiple virus strains. COVID-19 cases within the trial are currently being sequenced to provide critical complementary data to the efficacy readout.
CureVac has no access to the trial data.
We note that the company began the development of mRNA-based COVID-19 vaccine candidates in January 2020. CVnCoV is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs).
In December 2020, CureVac initiated the HERALD study with a 12µg dose of CVnCoV. In February 2021, it initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV.
Last month, CureVac along with partner GlaxoSmithKline (GSK - Free Report) announced the first preclinical data in a rat model, which showed that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
CureVac’s stock has surged 37.4% in the year so far against the industry’s decline of 4.1%.
There is a significant need for different vaccines across the globe to respond effectively to the emerging variants of COVID-19. Currently, players like Pfizer (PFE - Free Report) / BioNTech and Moderna (MRNA - Free Report) are leading the vaccine race with their approved vaccines.
CureVac currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>